Overview

Cann is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Our share register is maintained by Link Market Services Limited. Shareholders can view and update holding details, including Tax File Number or ABN, contact details and communications preferences, by visiting the share registry website www.linkmarketservices.com.au.Opens in new window

ASX Announcements

More Announcements

Annual Report 2021

DownloadOpens in new window